Giuseppe Stirparo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giuseppe Stirparo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Luzi
Data Archive for Social Sciences in Italy (DASSI) and Institute for Research on Population and Social Policies (CNR-IRPPS)
1 shared publication Fabio Palazzo
Institute for Research on Population and Social Policies, Italian National Research Council, Via Nizza 128, I-00198 Rome, Italy Tel.: +39-06-49932866, Fax: +39-06-85834506
1 shared publication- Fabio Palazzo
Institute for Research on Population and Social Policies, Italian National Research Council, Via Nizza 128, I-00198 Rome, Italy Tel.: +39-06-49932866, Fax: +39-06-85834506
1 shared publication - Fabrizio L. Ricci
Institute for System Analysis and Computer Science, National Research Council, Italy
1 shared publication Luca D Serbanati
1 shared publicationPaolo Martelletti
Headache Centre, Sant'Andrea Hospital, Department of Internal Medicine, Second School of Medicine, La Sapienza University, Rome, Italy
1 shared publication
Latest Publications
- 1 January 2006
- Vol. 124, 441-6
E-DIMEM: an economic model to estimate the costs of e-disease management.
In order to estimate the cost of generic clinical guidelines based on telemedicine services for chronic patients, an economic model (E-DIMEM) has been defined. This model is designed to help health suppliers and managers to plan for the future. It is essentially a workflow composed by diagnosis and therapeutic activities. The cost of each workflow activity is related to healthcare providers (activity agents), drugs, instruments, telemedicine services, and type of specialized healthcare centers used (hospital, clinics, etc.). This model performs multidimensional analysis. A web service based on the E-DIMEM has been implemented.
- 1 January 2006
- Vol. 124, 441-6
E-DIMEM: an economic model to estimate the costs of e-disease management.
In order to estimate the cost of generic clinical guidelines based on telemedicine services for chronic patients, an economic model (E-DIMEM) has been defined. This model is designed to help health suppliers and managers to plan for the future. It is essentially a workflow composed by diagnosis and therapeutic activities. The cost of each workflow activity is related to healthcare providers (activity agents), drugs, instruments, telemedicine services, and type of specialized healthcare centers used (hospital, clinics, etc.). This model performs multidimensional analysis. A web service based on the E-DIMEM has been implemented.
- Open Access
- 1 March 2003
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 4 (S1) , s88-s90
Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.
- 1 March 2003
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 4 (S1) , s88-s90
Open AccessDiscrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.